Active Investor Update
Oh, and did I mention that the shares are cheap? Standard & Poor's calculates that the company trades at just a forward PEG ratio (projected price/earnings divided by projected growth rate) of just 1.3 vs. a PEG of 1.7 for its peers in the consumer-products sector. The shares also pay a 2% dividend.
Johnson & Johnson looks like it has worked its way through the problems that drove shares down as low as $56 a share in February 2006. In the drug unit, which accounts for about 45% of sales, the company's pipeline of new products should start contributing to revenue in 2007, diminishing the effect of older products coming off patent. In the medical-device business, which accounts for 38% of sales, the company expects to be able to generate 5% to 6% revenue growth, a come-down from the heady 10% growth in the early part of the decade, but the segment's contribution to earnings growth will be healthier than the top-line number indicates, thanks to operating markets that climbed to 28.4% in 2005 from 24.2% in 2004. The acquisition of Pfizer's(PFE) consumer health care business (which will add brands such as Listerine, Lubriderm, Benadryl, Sudafed, Nicorette and Visine) will add about $4 billion in revenue to Johnson & Johnson's consumer segment (now 18% of sales). For the long haul, I like the company's continued commitment to research and development, which accounted for 13% of revenue in 2005, and its record of successful product innovation.TheStreet Premium Services
Jim Cramer's Action Alerts PLUS:
Trade right alongside a Wall Street pro — enjoy access to his Charitable Trust portfolio and be sent trade alerts BEFORE he makes a move. Learn MoreOptionsProfits:
Get 50+ trade ideas a week from the industry's top options experts. Plus — exclusive commentary on market trends and essential trading tools. Learn MoreReal Money:
Our team of professional Wall Street Pros — including Jim Cramer, Doug Kass, and Nicholas Vardy — delivers intelligent analysis, timely trade ideas, and colorful commentary. Learn MoreStocks Under $10:
Break into the market with small- and mid-cap stocks... all $10 or less! David Peltier tells you exactly which low-priced stocks he's buying and selling. Learn MoreTo begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
blog comments powered by Disqus
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note |
|
|---|---|---|---|---|
| 12,435.57 | 1,315.89 | 2,830.09 | 15.81 |
Oil *
101.94
|
|
UP
15.71 |
UP
2.57 |
DOWN
7.27 |
DOWN
0.44 |
10 Yr
1.58%
SPDR Gold
151.81
|
|
+0.13%
|
+0.20%
|
-0.26%
|
-2.71%
|
Data delayed 20 minutes |


Connect with TheStreet